Efficacy of canakinumab for mosaic tumor necrosis factor receptor associated periodic syndrome

Eur J Intern Med. 2024 May:123:156-158. doi: 10.1016/j.ejim.2024.01.034. Epub 2024 Feb 2.
No abstract available

Keywords: Canakinumab; Mosaic; Somatic mutation; TNFRSF1A; TRAPS syndrome.

Publication types

  • Letter
  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Female
  • Fever / drug therapy
  • Hereditary Autoinflammatory Diseases / drug therapy
  • Humans
  • Male
  • Receptors, Tumor Necrosis Factor, Type I / genetics
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • canakinumab
  • Antibodies, Monoclonal
  • Receptors, Tumor Necrosis Factor, Type I

Supplementary concepts

  • Periodic fever, familial, autosomal dominant